PYRAMEM

 

StockNo	Product description
EB0280-410-21	PYRAMEM (PIRACETAM) TABL. 400 MG X 40
EB0280-410-47	PYRAMEM (PIRACETAM) AMPOULE 1000MG/5 ML (20%)
EB0280-410-48	PYRAMEM (PIRACETAM) SYRUP 125 ML

 

COMPOSITION:
Piracetam 1000 mg in an ampoule of 5 ml;
1000 mg in 5 ml syrup;
400 mg in a tablet;

ACTION:
Pyramem improves the impaired functions of the cerebral cortex due to organic, inflammatory, traumatic, infectious or other causes. It improves the association processes, attention concentration and the state of "active alertness." These effects are based on the marked antihypnotic action, increase of the brain cells resistance to toxic agents, and stimulation of the macromolecules synthesis and bioenergic processes in the brain cells mitochondria. Pyramem increases the local blood flow.
Pyramem penetrates through the blood-brain and placental barriers.

PHARMACOKINETICS:
Pyramem is quickly absorbed after oral application, reaching maximum plasma concentration 1 h after administration. It is not metabolized. Its half-life is 4.5 hours. Pyramem possesses a tropism towards the gray brain substance, where therapeutic concentration is maintained for 2 to 8 h. maximum plasma concentration is obtained faster by the syrup than by the capsule and the tablet.

INDICATIONS:
Pyramem is indicated for the treatment of the psychoorganic syndrome due to disease of the cerebral blood vessels, metabolic disorders, inflammatory and degenerative diseases of the nervous system (primary degenerative dementia, multiinfarction dementia), cerebral trauma, traumatic cerebrasthenia, intoxications and other conditions involving reduced concentration ability, perception and memory impairment, fast mental fatigue, irritability, absentmindedness. Pyramem is indicated for treatment of retardation in children, postnatal traumatic injuries, children with behavioral deviations and learning difficulties, nocturnal enuresis, etc.
Ampoules are indicated for treatment of grave cerebral diseases: cranial and brain trauma, cerebral blood vessels disease, comatose states, acute psychic disorders due to intoxications, delirium.

SIDE EFFECTS:
Some increase of the excitation processes in the CNS may be observed, especially in adults: anxiety, sleep disorders, headache, tremor. In the gastrointestinal tract: salivation, nausea. Rarely, rashes.

PRECAUTIONS:
In cases of slight or moderate renal insufficiency (creatinin clearance up to 3 mg), only half of the therapeutic dose should be applied; in cases of grave renal insufficiency (creatinin clearance below 3 mg), 1/4 to 1/8 of the therapeutic dose must be prescribed.
Residual nitrogen and creatinin level should be controlled.

DRUG INTERACTIONS:
Pyramem slightly potentiates CNS stimulants and the central effects of the thyrotropic hormone, inducing tremor and anxiety. It may increase the effects of oral anticoagulants.

DOSAGE AND ADMINISTRATION:
Orally and parenterally. The course of treatment is from 2.5 to 3 months. In grave cases, from 6 to 12 months; the course may be repeated after some time. The usual daily dose is 2.4 to 4.8 g.

MEDICINAL FORM AND PACKAGE:
Ampoules of 1000 mg/5 ml (20 %), in packs of 10 and 50.
Syrup in flasks of 125 ml.
Tablets of 400 mg in packs of 40.

STORAGE:
At room temperature (15-30 C), in places protected from direct sunlight.

EXPIRY:
Ampoules: 5 (five) years.
Syrup: 2 (two) years.
Tablets: 3 (three) years.